Search results for:
aprepitant
aprepitant
Drug Name |
Form |
Strength |
Formulary Unrestricted |
Formulary Restricted |
Non-Formulary |
Interchange |
Emend |
CAPSULE, ORAL |
40 mg, 80 mg, 125 mg |
|
|
|
|
Cinvanti |
EMULSION, INTRAVENOUS |
130 mg/18 mL |
|
|
|
|
Emend for Injection |
POWDER FOR INJECTION, INTRAVENOUS |
150 mg |
|
|
|
|
Emend |
SUSPENSION, ORAL |
125 mg |
|
|
|
|
Last updated: Mar. 30, 2020
- Formulary, Not Routinely Stocked: Emend --> 80 mg capsule, 125 mg capsule
Emend criteria for use in PONV
Emend ORAL CAPSULE --> For prevention (not treatment) of post-op nausea/vomiting, restricted to a one time dose of 40 mg PO is given before surgery. The P&T Committee approved the use of the 40 mg dose for this indication, but recommended that the use should be limited to the approved criteria.
For chemotherapy associated nausea, restricted to situations that meet all of the following:
Fosaprepitant (Emend IV) / Cinvanti Formulary Interchange/Restrictions
Fosaprepitant is considered formulary restricted to oncology for use in adults and pediatrics both inpatient and outpatient for the prevention of CINV. For adults, both fosaprepitant and Cinvanti will be approved per formulary policy for adult use in CINV, restricted to Oncology, and the selection of product will depend on cost-effectivenesss for the time period, specific setting, or patient situation. The pharmacist may interchange fosaprepitant 150 mg and Cinvanti 130 mg as appropriate per above statement. May give Cinvanti IV push over 2 minutes. Because of the 130 mg dose of Cinvanti given in MEC, days 2 and 3 of oral aprepitant have been omitted with this interchange.
Emend oral suspension should be considered non-formulary, not stocked. When suspension is ordered for pediatric patients it will be interchanged to Emend IV according to the table below. If the patient is 12 to 17 years old and can swallow capsules, there is a three-day regimen available as another option, but is rarely used at Huntsville Hospital. If the suspension is ordered in adults, it will be interchanged to either Cinvanti 130 mg to be given IV push over 2 minutes times one dose, or fosaprepitant 150 mg over 30 minutes x 1 dose, whichever product is more cost effective at that time or for a given patient or setting.
6 months to 2 years
2 to 12 years
12 to 17 years
ADULTS
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
Reviewed: September 26, 2006 (Emend for PONV), 27 Feb 2018 (Cinvanti), 24 March, 2020 (Emend suspension)